The Michael J. Fox Foundation has evolved its Parkinson’s Progression Markers Initiative into the Parkinson’s Precision Medicine Initiative, focusing on tailored treatments based on individual biological differences in patients. With over 4,200 clinical participants and more than 47,000 online contributors, this initiative aims to innovate clinical trial designs and ensure treatments align with specific patient profiles, all while advancing research on Parkinson’s disease.
